Gardasil 9
human papillomavirus 9-valent vaccine (recombinant, adsorbed)
Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)
Keep this leaflet. You may need to read it again.
If you have any further questions, please ask your doctor, pharmacist or nurse.
If you or your child get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
What Gardasil 9 is and what it is used for
What you need to know before you or your child receive Gardasil 9
How Gardasil 9 is given
Possible side effects
How to store Gardasil 9
Contents of the pack and other information
Gardasil 9 is a vaccine for children and adolescents from 9 years of age and adults. It is given to protect against diseases caused by Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52
and 58.
These diseases include pre-cancerous lesions and cancers of the female genitals (cervix, vulva, and vagina), pre-cancerous lesions and cancers of the anus and genital warts in males and females.
Gardasil 9 has been studied in males 9 to 26 years of age and females 9 to 45 years of age. Gardasil 9 protects against the HPV types that cause most cases of these diseases.
Gardasil 9 is intended to prevent these diseases. The vaccine is not used to treat HPV related diseases. Gardasil 9 does not have any effect in individuals who already have a persistent infection or disease associated with any of the HPV types in the vaccine. However, in individuals who are already infected with one or more of the vaccine HPV types, Gardasil 9 can still protect against diseases associated with the other HPV types in the vaccine.
Gardasil 9 cannot cause HPV-related diseases.
When an individual is vaccinated with Gardasil 9, the immune system (the body’s natural defence system) stimulates production of antibodies against the nine vaccine HPV types, to help protect against the diseases caused by these viruses.
If you or your child receive a first dose of Gardasil 9, you have to complete the full vaccination course with Gardasil 9.
If you or your child already received an HPV vaccine, ask your doctor if Gardasil 9 is right for you. Gardasil 9 should be used in accordance with official guidelines.
is allergic to any of the active substances or any of the other ingredients of this vaccine (listed
under “other ingredients”, in section 6).
developed an allergic reaction after receiving a dose of Gardasil or Silgard (HPV types 6, 11,
16, and 18) or Gardasil 9.
Talk to your doctor, pharmacist or nurse if you or your child:
has a bleeding disorder (a disease that makes you bleed more than normal), for example
haemophilia;
has a weakened immune system, for example due to a genetic defect, HIV infection or
medicines that affect the immune system;
suffer from an illness with high fever. However, a mild fever or upper respiratory infection (for
example having a cold) itself is not a reason to delay vaccination.
Fainting, sometimes accompanied by falling, can occur (mostly in adolescents) following any needle injection. Therefore tell the doctor or nurse if fainting occurred with a previous injection.
As with any vaccine, Gardasil 9 may not fully protect all of those who get the vaccine. Gardasil 9 will not protect against every type of Human Papillomavirus. Therefore appropriate
precautions against sexually transmitted disease should continue to be used.
The duration of protection is not yet known. Longer term follow-up studies are ongoing to determine whether a booster dose is needed.
Tell your doctor or pharmacist if you or your child are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Gardasil 9 can be given with a combined booster vaccine containing diphtheria (d) and tetanus (T) with either pertussis [acellular, component] (ap) and/or poliomyelitis [inactivated] (IPV) (dTap,
dT-IPV, dTap-IPV vaccines) at a separate injection site (another part of your body, for example the other arm or leg) during the same visit.
Gardasil 9 may not have an optimal effect if used with medicines that suppress the immune system. Hormonal contraceptives (for example the pill) did not reduce the protection obtained by Gardasil 9.
If you are pregnant, think that you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you receive this vaccine.
Gardasil 9 may be given to women who are breast-feeding or intend to breast-feed.
Gardasil 9 may slightly and temporarily affect the ability to drive or use machines (see section 4
“Possible side effects”).
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially
‘sodium-free’.
Gardasil 9 is given as an injection by your doctor. Gardasil 9 is intended for adolescents and adults from 9 years of age onwards.
-If you are from 9 to and including 14 years of age at time of first injection
ardasil 9 can be administered according to a 2-dose schedule: First injection: at chosen date
Second injection: given between 5 and 13 months after first injection
If the second vaccine dose is administered earlier than 5 months after the first dose, a third dose should always be administered.
-
ardasil 9 can be administered according to a 3-dose schedule:
First injection: at chosen date
Second injection: 2 months after first injection (not earlier than one month after the first dose)
Third injection: 6 months after first injection (not earlier than 3 months after the second dose)
All three doses should be given within a 1-year period. Please speak to your doctor for more information.
-If you are from 15 years of age at time of first injection
ardasil 9 should be administered according to a 3-dose schedule:
First injection: at chosen date
Second injection: 2 months after first injection (not earlier than one month after the first dose)
Third injection: 6 months after first injection (not earlier than 3 months after the second dose)
All three doses should be given within a 1-year period. Please speak to your doctor for more information.
It is recommended that individuals who receive a first dose of Gardasil 9 complete the vaccination course with Gardasil 9.
Gardasil 9 will be given as an injection through the skin into the muscle (preferably the muscle of the upper arm or thigh).
If a scheduled injection is missed, your doctor will decide when to give the missed dose.
It is important that you follow your doctor or nurse’s instructions regarding return visits for the follow- up doses. If you forget or are not able to go back to your doctor at the scheduled time, ask your doctor for advice. When Gardasil 9 is given as your first dose, the completion of the vaccination course should be done with Gardasil 9, and not another HPV vaccine.
If you have any further questions on the use of this vaccine, ask your doctor or pharmacist.
Like all vaccines, this vaccine can cause side effects, although not everybody gets them. The following side effects can be seen after the use of Gardasil 9:
When Gardasil 9 was given with a combined diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] booster vaccine during the same visit, there was more injection-site swelling.
Fainting, sometimes accompanied by shaking or stiffening, has been reported. Although fainting episodes are uncommon, patients should be observed for 15 minutes after they receive HPV vaccine.
Allergic reactions have been reported. Some of these reactions have been severe. Symptoms may
include difficulty breathing and wheezing.
As with other vaccines, side effects that have been reported during general use include: muscle weakness, abnormal sensations, tingling in the arms, legs and upper body, or confusion (Guillain- Barré syndrome, acute disseminated encephalomyelitis); bleeding or bruising more easily than normal and skin infection at the injection site.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this vaccine out of the sight and reach of children.
Do not use this vaccine after the expiry date which is stated on the carton and vial label after EXP. The expiry date refers to the last day of that month.
Store in a refrigerator (2 ºC - 8 ºC). Do not freeze. Keep the vial in the outer carton in order to protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substances are: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16, 18, 31, 33, 45, 52, and 58).
1 dose (0.5 ml) contains approximately:
Human Papillomavirus1 Type 6 L1 protein2,3 30 micrograms Human Papillomavirus1 Type 11 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 16 L1 protein2,3 60 micrograms Human Papillomavirus1 Type 18 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 31 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 33 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 45 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 52 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 58 L1 protein2,3 20 micrograms
1Human Papillomavirus = HPV
2L1 protein in the form of virus like particles produced in yeast cells (Saccharomyces cerevisiae
CANADE 3C-5 (Strain 1895)) by recombinant DNA technology.
3adsorbed on amorphous aluminium hydroxyphosphate sulfate adjuvant (0.5 milligrams Al).
Amorphous aluminium hydroxyphosphate sulfate is included in the vaccine as an adjuvant. Adjuvants are included to improve the immune response of vaccines.
The other ingredients in the vaccine suspension are: sodium chloride, histidine, polysorbate 80, borax and water for injections.
1 dose of Gardasil 9 suspension for injection contains 0.5 ml.
Prior to agitation, Gardasil 9 may appear as a clear liquid with a white precipitate. After thorough agitation, it is a white, cloudy liquid.
Gardasil 9 is available in a pack of 1.
Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
MSD Belgium
Tél/Tel: +32 (0) 27766211
UAB Merck Sharp & Dohme Tel.: +370.5.2780.247
Мерк Шарп и Доум България ЕООД,
тел.: + 359 2 819 3737
MSD Belgium
Tél: +32 (0) 27766211
Merck Sharp & Dohme s.r.o. Tel.: +420 233 010 111
MSD Pharma Hungary Kft. Tel.: + 36.1.888.5300
MSD Danmark ApS Tlf: + 45 4482 4000
Merck Sharp & Dohme Cyprus Limited. Tel: 8007 4433 (+356 99917558)
MSD Sharp & Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
Merck Sharp & Dohme B.V.
Tel: 0800 9999000
(+31 23 5153153)
Merck Sharp & Dohme OÜ Tel.: +372 6144 200
MSD (Norge) AS Tlf: +47 32 20 73 00
MSD Α.Φ.Β.Ε.Ε.
Τηλ: +30 210 98 97 300
Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044
Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00
MSD Polska Sp. z o.o. Tel.: +48.22.549.51.00
MSD France
Tél: +33 (0) 1 80 46 40 40
Merck Sharp & Dohme, Lda Tel: +351 21 4465700
Merck Sharp & Dohme d.o.o. Tel: +385 1 66 11 333
Merck Sharp & Dohme Romania S.R.L Tel: + 4021 529 29 00
Merck Sharp & Dohme Ireland (Human Health) Limited
Tel: +353 (0)1 2998700
Merck Sharp & Dohme, inovativna zdravila d.o.o.
Tel: +386.1.520.4201
Vistor hf.
Sími: + 354 535 7000
Merck Sharp & Dohme, s. r. o Tel: +421 2 58282010
MSD Italia S.r.l.
Tel: 800 23 99 89 (+39 06 361911)
MSD Finland Oy
Puh/Tel: +358 (0)9 804 650
Merck Sharp & Dohme Cyprus Limited
Τηλ: 800 00 673 (+357 22866700)
Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488
SIA Merck Sharp & Dohme Latvija Tel: +371.67364.224
Merck Sharp & Dohme Ireland (Human Health) Limited
Tel: +353 (0)1 2998700
------------------------------------------------------------------------------------------------------------------------
Gardasil 9 suspension for injection:
Gardasil 9 may appear as a clear liquid with a white precipitate prior to agitation.
Shake well before use to make a suspension. After thorough agitation, it is a white, cloudy
liquid.
Inspect the suspension visually for particulate matter and discolouration prior to administration.
Discard the vaccine if particulates are present and/or if it appears discoloured.
Withdraw the 0.5 ml dose of vaccine from the vial using a sterile needle and syringe.
Inject immediately using the intramuscular (IM) route, preferably in the deltoid are of the upper
arm or in the higher anterolateral area of the thigh.
The vaccine should be used as supplied. The full recommended dose of the vaccine should be
used.
Any unused vaccine or waste material should be disposed of in accordance with local requirements.